The Interview World’s Post

Four in five adults with diabetes experience diabetes stigma. Diabetes stigma refers to the negative social judgements, stereotypes, and biases about diabetes. A recent international consensus statement on diabetes stigma, which several PSAD members are authors on, was published in The Lancet Diabetes and Endocrinology. It summarises evidence for the harmful effects of stigma and translates evidence into 7 actionable commitments that can help bring an end to diabetes stigma. Read the full manuscript here: https://lnkd.in/dxi-bRVW

The treatment of kidney disease, particularly chronic kidney disease (CKD), involves a variety of medications that aim to slow disease progression, manage symptoms, and prevent complications. https://lnkd.in/dMkmqs7y #kidneyhealth #diabetes #medication #nephrology #health #telekidney

A JAMA Patient Page on obesity in adults. Obesity is a condition of excess body fat that affects 800 million people worldwide and approximately 42% of adults in the US. Obesity leads to a higher risk of death, heart disease, high blood pressure, diabetes, high cholesterol, gallbladder disease, metabolic dysfunction–associated steatotic liver disease, stroke, sleep apnea, osteoarthritis, depression, anxiety, and certain cancers (such as breast and colorectal cancers). Intensive behavioral programs can achieve weight loss of 5% to 10% after 6 to 12 months. FDA-approved injection medications for obesity include liraglutide, semaglutide, and tirzepatide; along with healthy lifestyle changes, they can result in an 8% to 21% weight loss. Surgery (laparoscopic gastric sleeve gastrectomy, Roux-en-Y gastric bypass) results in weight loss of 25% to 30% at 12 months. https://lnkd.in/etKN2FKp

Our SVP and Chief Medical Officer, Michael L. Kyle, M.D., discusses the importance of obesity phenotypes when treating this disease. To read more, check out the link below.

Revolutionizing Diabetes Care: The Role of Endocrinology in Innovative Treatments https://lnkd.in/eMucf3GJ https://lnkd.in/eTEtQBJn Diabetes is a complex and chronic condition that affects millions of people worldwide. As the prevalence of diabetes continues to rise, the field of endocrinology is at the forefront of developing innovative treatments that improve patient outcomes and quality of life. This blog post explores the latest advancements in diabetes care, highlighting the crucial role of endocrinologists in driving these innovations. One of the most significant developments in diabetes care is the shift towards personalized medicine. Endocrinologists are using genetic and molecular profiling to tailor treatments to individual patients, ensuring more effective management of the disease. #Endocrinology #Diabetes care #Personalized medicine #Glucose monitoring #Insulin delivery #Diabetes management #Endocrinologists #Innovative treatments #Diabetes prevention #Metabolic disorders

I discuss the importance of knowing your obesity "phenotype" in my article in Life Science Leader. Generally speaking most obesity patients will fit into one of the four categories (or phenotypes) below:   🔹Slow Burn 🔹Hungry Gut 🔹Hungry Brain 🔹Emotional Eater   Knowing which phenotype you fall into can help guide your treatment plan, which improves its effectiveness. To learn more a about obesity phenotypes and treatment options available to you, check out the link below.   https://bit.ly/3TKKTg6

🚨 Hypertension: A Call for Action! As we stand on the threshold of World Hypertension Day this month, let's unite in remembrance and action: Did you know❓ The World Health Organization and Imperial College London reported a staggering rise of over 1 billion adults aged 30-79 years with hypertension in just 30 years (1)?  📊 This alarming statistic is even more concerning, considering hypertension is a silent killer. Nearly half of those tested didn't even know they had hypertension. 🚨Plasma Renin Activity (PRA), a crucial player in the Renin-Angiotensin-Aldosterone Axis, especially in resistant hypertension. During normal homeostasis, renin is released under conditions of dehydration or low blood pressure. 📈🩸Renin enzymatic activity promotes the cleavage of Angiotensinogen and generation of Angiotensin I, which in turn is transformed into Angiotensin II and activates aldosterone release. 💡Dr J David Spence, Professor of Neurology & Clinical Pharmacology at Western University, London, Ontario, emphasizes the “measurement of stimulated plasma renin activity is much less costly than tests routinely done in patients with severe hypertension.”(2). 📚In the American Journal of Hypertension, John Laragh and Jean Sealey noted similar benefits of PRA testing: In the hypertensive patient PRA testing can guide initiation, addition or subtraction of anti-V or anti-R antihypertensive drug types to thereby improve [blood pressure] control and prognosis while reducing drug type usage and cost.(3). 🔍 Introducing the DBC PRA ELISA Kit 🔍 It  is a convenient, inexpensive and accurate resource to evaluate resistant hypertension. 🔗 Learn more about the DBC PRA ELISA kit here: https://lnkd.in/dJ4mvVuh Information about DBC’s Aldosterone ELISA kit can be found here: https://lnkd.in/d5Me5NXS 💻Visit us at dbc-labs.com/  for any other information, or call us at 📞519-681-8731 #HealthcareInnovation #HypertensionAwareness #MedicalResearch #HealthTech #LabtoBedside #PatientCare #DBCInsights

"In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years." In addition to what appears to be cardiovascular protective effects from semaglutide before weigh loss even occurs, it's incredibly exciting to see these results as we know the recidivism rate in weight loss is extremely high. It also highlights the importance of combining GLP medication with intensive lifestyle interventions for optimal outcomes. This SELECT trial had a lower average weight loss (mean 10.2% at 208 weeks) than the STEP trials (mean 14.9% at 68 weeks) which is likely due to the lifestyle interventions (caloric restriction and exercises) that were required of the participants in STEP. As the pioneer of comprehensive obesity treatment, Calibrate continues to expand access to obesity care through our commercial program. Our proven results combine our lifestyle intervention, accountability coaching, and medication as a tool, not the entire treatment, as part of a larger, comprehensive approach to weight management to ensure that the right members are getting the right treatments at the right time for sustainable results. https://lnkd.in/gM-2xmaK

Better #patientengagement occurs when treatment focuses on the whole person, as Currax Pharmaceuticals LLC points out in the insightful article by their CMO, Michael L. Kyle, M.D., regarding treatment for #obesity.  Taking the individual patient’s obesity “phenotype” into account should lead to better #pharmaceutical #adherence and patient outcomes. https://lnkd.in/gn9A6Ewm

#females #exercise #metabolism https://lnkd.in/g-Ce6zxk Effect of #resistance #training volume on body #adiposity, metabolic risk, and #inflammation in #postmenopausal and older females: Systematic review and meta-analysis of randomized controlled trials.                                    Highlights • Resistance training improves body adiposity, metabolic risk, and inflammation in postmenopausal and older females. • High-volume resistance training elicits greater improvements in metabolic risk and inflammation outcomes. • We identified an optimal dosage for resistance training prescription in this population.